HIỆU QUẢ CỦA NIVOLUMAB KẾT HỢP HOÁ TRỊ TRONG ĐIỀU TRỊ UNG THƯ DẠ DÀY GIAI ĐOẠN MUỘN TẠI VIỆT NAM: BÁO CÁO LOẠT CA BỆNH

Abstract

Objective: To report outcomes of combined chemotherapy and immunotherapy (nivolumab) in four patients with advanced gastric cancer. Patients and Methods: We describe a case series of four patients: three received modified FOLFOX6 (mFOLFOX6) plus nivolumab and one received SOX (S-1 [TS-1] + oxaliplatin) plus nivolumab. Tumor response was assessed according to RECIST v1.1. Adverse events were monitored and graded according to CTCAE. Clinical and radiologic follow-up were performed at regular intervals. Results: Two patient achieved a complete response (CR). The remaining two patients achieved sustained favorable responses and continue on treatment: one patient has prolonged disease control with a progression-free survival (PFS) of 40 months to date. Treatment was well tolerated overall. Adverse events were predominantly mild, mostly grade 1. Conclusions: The combination of chemotherapy with nivolumab demonstrated promising activity and a favorable safety profile in this small series of advanced gastric cancer patients. These preliminary results suggest potential broader applicability of immunotherapy in this subgroup in clinical practice.